SecBot SecBot
SECBOTREPLAY Home › Report › CNTA

CNTA · Centessa Pharmaceuticals (CNTA) is being acquired by Eli Lilly (LILY)…

Centessa Pharmaceuticals plc · PREM14A filed Apr 17, 2026 at 16:45 ET

At the news

BULLISHIMPACT 9/10

PREM14A filed Apr 17, 2026 at 16:45 ET

Centessa Pharmaceuticals (CNTA) is being acquired by Eli Lilly (LILY) in a $7.8B deal structured as a Scheme of Arrangement. Shareholders will receive $38.00 in cash per share plus a contingent value right (CVR) worth up to $9.00 per share based on future milestones. The deal, recommended by Centessa's board, is expected to close in Q3 2026 pending shareholder and regulatory approval.

  • Eli Lilly is acquiring Centessa Pharmaceuticals for $38.00 per share in cash, plus a contingent value right (CVR) worth up to $9.00 per share.
  • The total deal value is approximately $7.8 billion, including the CVR component.
  • Centessa's board unanimously recommends shareholders vote in favor of the transaction.
  • The deal structure is a Scheme of Arrangement under UK law, requiring approval from both shareholders and the UK High Court.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access